These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15042527)

  • 1. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31 Suppl 2():2-6. PubMed ID: 28140105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
    Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
    Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
    Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
    Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearing minimal residual disease with rituximab consolidation therapy.
    Brugger W
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
    Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
    J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in the treatment of lymphoma with autologous transplantation.
    Moskowitz AJ; Moskowitz CH
    Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
    Gianni AM; Cortelazzo S; Magni M; Martelli M;
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S10-3. PubMed ID: 11840155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma.
    Thieblemont C; Antal D; Lacotte-Thierry L; Delwail V; Espinouse D; Michallet AS; Traulle C; Bouafia-Sauvy F; Giraud C; Salles G; Guilhot F; Coiffier B
    Cancer; 2005 Oct; 104(7):1434-41. PubMed ID: 16104036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
    Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
    Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
    Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
    J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.